person · Reporting owner

Dier Mardi

Disclosed activity across 7 companies

Tapewire entity: 62346
SEC CIK: 0001574591

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACELYRIN, Inc.SLRN · Entity 79310	CFO and CBO	May 09, 2023	May 11, 2023
Adamas Pharmaceuticals IncADMS · Entity 133085	Director	June 02, 2021	June 04, 2021
MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441	EVP and CFO	March 04, 2026	March 07, 2026
Oric Pharmaceuticals, Inc.ORIC · Entity 4765	Director	January 02, 2026	January 06, 2026
Prelude Therapeutics IncPRLD · Entity 5561	Director	June 12, 2025	June 13, 2025
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337	CFO & Executive Vice President	October 14, 2022	October 17, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACELYRIN, Inc.

Report date May 09, 2023 · Filed May 11, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,556	Reported balance After 2023-05-09 transaction · row 1 1 source row Row 1 · 2023-05-09 · Purchase · Acquired 5,556 · Balance 5,556 F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO").
Common StockSEC Table I · non-derivative	IndirectSee footnote	875	Reported balance After 2023-05-09 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-05-09 · Purchase · Acquired 875 · Balance 875 F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). F2: The shares are held of record by one of the Reporting Person's children.
Common StockSEC Table I · non-derivative	IndirectSee footnote	875	Reported balance After 2023-05-09 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2023-05-09 · Purchase · Acquired 875 · Balance 875 F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). F3: The shares are held of record by another one of the Reporting Person's children.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2032-11-20	Direct	0	Reported balance After 2023-05-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-05-09 · Other · Disposed 673,621 · Balance 0 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F5: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2032-11-20	Direct	673,621	Reported balance After 2023-05-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-05-09 · Other · Acquired 673,621 · Balance 673,621 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F5: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	0	Reported balance After 2023-05-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-05-09 · Other · Disposed 85,226 · Balance 0 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	85,226	Reported balance After 2023-05-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-05-09 · Other · Acquired 85,226 · Balance 85,226 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO").

F2: The shares are held of record by one of the Reporting Person's children.

F3: The shares are held of record by another one of the Reporting Person's children.

F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F5: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F6: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Adamas Pharmaceuticals Inc

Report date June 02, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,000	Reported balance After 2021-06-02 transaction · row 1 1 source row Row 1 · 2021-06-02 · Grant · Acquired 5,000 · Balance 10,000 F1: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2031-06-01	Direct	10,000	Reported balance After 2021-06-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-02 · Grant · Acquired 10,000 · Balance 10,000 F2: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

F2: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

MADRIGAL PHARMACEUTICALS, INC.

Report date March 04, 2026 · Filed March 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	12,490	Ending reported balance After 2026-03-06 transaction · row 13 13 source rows · reconciled sequence Row 1 · 2026-03-04 · Grant · Acquired 5,215 · Balance 14,472 F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. Row 2 · 2026-03-06 · Sale · Disposed 646 · Balance 13,826 F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Row 3 · 2026-03-06 · Sale · Disposed 40 · Balance 13,786 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. Row 4 · 2026-03-06 · Sale · Disposed 420 · Balance 13,366 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Row 5 · 2026-03-06 · Sale · Disposed 80 · Balance 13,286 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive. Row 6 · 2026-03-06 · Sale · Disposed 160 · Balance 13,126 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive. Row 7 · 2026-03-06 · Sale · Disposed 40 · Balance 13,086 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. Row 8 · 2026-03-06 · Sale · Disposed 120 · Balance 12,966 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive. Row 9 · 2026-03-06 · Sale · Disposed 116 · Balance 12,850 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive. Row 10 · 2026-03-06 · Sale · Disposed 160 · Balance 12,690 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive. Row 11 · 2026-03-06 · Sale · Disposed 80 · Balance 12,610 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive. Row 12 · 2026-03-06 · Sale · Disposed 80 · Balance 12,530 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive. Row 13 · 2026-03-06 · Sale · Disposed 40 · Balance 12,490 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $434.80 · Expires 2036-03-04	Direct	6,519	Reported balance After 2026-03-04 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-03-04 · Grant · Acquired 6,519 · Balance 6,519 F12: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.

F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive.

F12: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Oric Pharmaceuticals, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2036-01-01	Direct	40,000	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 40,000 · Balance 40,000 F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

Prelude Therapeutics Inc

Report date June 12, 2025 · Filed June 13, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2035-06-11	Direct	38,000	Reported balance After 2025-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-12 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Ultragenyx Pharmaceutical Inc.

Report date October 14, 2022 · Filed October 17, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	66,695	Reported balance After 2022-10-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-10-14 · Sale · Disposed 1,629 · Balance 66,695 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PORTOLA PHARMACEUTICALS INC

Report date July 02, 2020 · Filed July 02, 2020

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-07-02 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2020-07-02 · Disposition to issuer · Disposed 39,563 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	10	Reported balance After 2020-06-18 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2020-06-18 · Grant · Acquired 10 · Balance 10 F2: The acquisition of 10 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-07-02 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2020-07-02 · Disposition to issuer · Disposed 10 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-02 · Disposition to issuer · Disposed 48,750 · Balance 0 F3: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio").
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-07-02 · Disposition to issuer · Disposed 24,375 · Balance 0 F4: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.79 · Expires 2030-01-30	Direct	0	Reported balance After 2020-07-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-07-02 · Disposition to issuer · Disposed 65,000 · Balance 0 F5: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.79 · Expires 2030-01-30	Direct	0	Reported balance After 2020-07-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-07-02 · Disposition to issuer · Disposed 32,500 · Balance 0 F6: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-07-02 · Disposition to issuer · Disposed 371,545 · Balance 0 F7: In connection with the Merger, these options were accelerated and canceled without payment.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-07-02 · Disposition to issuer · Disposed 32,291 · Balance 0 F8: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2: The acquisition of 10 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.

F3: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio").

F4: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time.

F5: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F6: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F7: In connection with the Merger, these options were accelerated and canceled without payment.

F8: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 09, 2023 Filed May 11, 2023 20:51 UTC	ACELYRIN, Inc. SLRN · Entity 79310	PurchaseCommon Stock	5,556	$18.00	$100,008.00	Disclosure SEC source: 0001209191-23-028864 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,556 F1 · shares: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). Read SEC document
May 04, 2023 Filed May 4, 2023 19:59 UTC	ACELYRIN, Inc. SLRN · Entity 79310	GrantEmployee Stock Option (right to buy) · Derivative	85,226	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-027513 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,226 Underlying: Class A Common Stock · 85,226 shares Expires 2033-05-03 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
October 14, 2022 Filed Oct 17, 2022 22:49 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	1,629	$40.16	$65,420.64	Disclosure SEC source: 0001209191-22-053884 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,695 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
October 12, 2022 Filed Oct 14, 2022 16:58 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	3,484	$38.22	$133,158.48	Disclosure SEC source: 0001209191-22-053647 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,324 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
September 16, 2022 Filed Sep 20, 2022 01:39 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-050670 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,808 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
June 17, 2022 Filed Jun 17, 2022 20:19 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	GrantStock Option (right to buy) · Derivative	53,700	$0.00 Strike: $3.75	$0.00	Disclosure SEC source: 0001209191-22-038197 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,700 Underlying: Common Stock · 53,700 shares Expires 2032-06-16 F1 · derivative.exercise_date: (A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022. Read SEC document
June 17, 2022 Filed Jun 22, 2022 16:13 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	34,300	$0.00 Strike: $4.74	$0.00	Disclosure SEC source: 0001562180-22-005297 · primarydocument.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,300 Underlying: Common Stock · 34,300 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
March 03, 2022 Filed Mar 3, 2022 23:12 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	420	$64.55	$27,111.00	Disclosure SEC source: 0001209191-22-015833 · doc4.xml · nonDerivative · entry 3 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,808 F3 · kind: The sales on March 3, 2022 reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:12 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	24,900	$0.00 Strike: $67.37	$0.00	Disclosure SEC source: 0001209191-22-015833 · doc4.xml · derivative · entry 4 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 24,900 shares Expires 2032-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:12 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	14,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-015833 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,228 F2 · shares: Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:12 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	534	$66.62	$35,575.08	Disclosure SEC source: 0001209191-22-015833 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,228 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). Read SEC document
October 14, 2021 Filed Oct 14, 2021 22:33 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	3,261	$81.16	$264,662.76	Disclosure SEC source: 0001209191-21-060504 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,762 F2 · kind: The transaction reported in this row on this Form 4 was effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.55 to $81.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
October 12, 2021 Filed Oct 14, 2021 22:33 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	3,477	$82.79	$287,860.83	Disclosure SEC source: 0001209191-21-060504 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,023 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). Read SEC document
June 18, 2021 Filed Jun 22, 2021 17:40 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	23,344	$0.00 Strike: $31.02	$0.00	Disclosure SEC source: 0001209191-21-042471 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,344 Underlying: Common Stock · 23,344 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 16, 2021 Filed Jun 17, 2021 19:42 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	GrantStock Option (right to buy) · Derivative	16,625	$0.00 Strike: $19.03	$0.00	Disclosure SEC source: 0001209191-21-041738 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,625 Underlying: Common Stock · 16,625 shares Expires 2031-06-15 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 16, 2022 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document
June 02, 2021 Filed Jun 4, 2021 16:13 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $5.21	$0.00	Disclosure SEC source: 0001328143-21-000056 · wf-form4_162283761559047.xml · derivative · entry 2 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-01 F2 · derivative.exercise_date: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document
June 02, 2021 Filed Jun 4, 2021 16:13 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001328143-21-000056 · wf-form4_162283761559047.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:38 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	11,000	$0.00 Strike: $142.47	$0.00	Disclosure SEC source: 0001209191-21-017541 · doc4.xml · derivative · entry 2 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-03-01 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:38 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	5,500	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017541 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
October 12, 2020 Filed Oct 13, 2020 21:52 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $95.50	$0.00	Disclosure SEC source: 0001209191-20-054709 · doc4.xml · derivative · entry 2 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-10-12 F2 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document
October 12, 2020 Filed Oct 13, 2020 21:52 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	40,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-054709 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document
September 29, 2020 Filed Sep 29, 2020 20:09 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	PurchaseCommon Stock	10,000	$19.00	$190,000.00	Disclosure SEC source: 0001209191-20-052403 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document
September 24, 2020 Filed Sep 28, 2020 19:35 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (right to buy) · Derivative	3,458	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001209191-20-052266 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,458 Underlying: Common Stock · 3,458 shares Expires 2030-09-23 F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on September 24, 2020 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:25 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerRestricted Stock Units · Derivative	32,291	$0.00	$0.00	Disclosure SEC source: 0001209191-20-040307 · doc4.xml · derivative · entry 9 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,291 shares Expires not disclosed F8 · derivative.exercise_price: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio. F8 · derivative.exercise_date: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio. F8 · derivative.expiration_date: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:25 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerStock Option (Right to Buy) · Derivative	371,545	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-040307 · doc4.xml · derivative · entry 8 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 371,545 shares Expires not disclosed F7 · derivative.exercise_price: In connection with the Merger, these options were accelerated and canceled without payment. F7 · price: In connection with the Merger, these options were accelerated and canceled without payment. F7 · derivative.exercise_date: In connection with the Merger, these options were accelerated and canceled without payment. F7 · derivative.expiration_date: In connection with the Merger, these options were accelerated and canceled without payment. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:25 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerStock Option (Right to Buy) · Derivative	32,500	Not disclosed Strike: $12.79	Not disclosed	Disclosure SEC source: 0001209191-20-040307 · doc4.xml · derivative · entry 7 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2030-01-30 F6 · price: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F6 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:25 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerStock Option (Right to Buy) · Derivative	65,000	$5.21 Strike: $12.79	$338,650.00	Disclosure SEC source: 0001209191-20-040307 · doc4.xml · derivative · entry 6 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2030-01-30 F5 · price: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F5 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:25 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerPerformance Stock Units · Derivative	24,375	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-040307 · doc4.xml · derivative · entry 5 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,375 shares Expires not disclosed F4 · derivative.exercise_price: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time. F4 · price: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time. F4 · derivative.exercise_date: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time. F4 · derivative.expiration_date: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:25 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerPerformance Stock Units · Derivative	48,750	$0.00	$0.00	Disclosure SEC source: 0001209191-20-040307 · doc4.xml · derivative · entry 4 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,750 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio"). F3 · derivative.exercise_date: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio"). F3 · derivative.expiration_date: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio"). Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:25 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerCommon Stock	10	$18.00	$180.00	Disclosure SEC source: 0001209191-20-040307 · doc4.xml · nonDerivative · entry 3 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:25 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerCommon Stock	39,563	$18.00	$712,134.00	Disclosure SEC source: 0001209191-20-040307 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. Read SEC document
June 18, 2020 Filed Jul 2, 2020 16:25 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	10	$8.36	$83.60	Disclosure SEC source: 0001209191-20-040307 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10 F2 · kind: The acquisition of 10 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. F2 · shares: The acquisition of 10 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document
June 03, 2020 Filed Jun 5, 2020 18:09 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $2.70	$0.00	Disclosure SEC source: 0001209191-20-034777 · doc4.xml · derivative · entry 2 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-02 F2 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 3, 2020, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document
June 03, 2020 Filed Jun 5, 2020 18:09 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-034777 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the date 1 year from June 3, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document
April 23, 2020 Filed Apr 27, 2020 16:41 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	GrantStock Option (right to buy) · Derivative	33,250	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-20-025807 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,250 Underlying: Common Stock · 33,250 shares Expires 2030-04-22 F1 · derivative.exercise_date: One thirty-sixth (1/36) of the shares subject to the option shall vest May 23, 2020, and an additional thirty-sixth (1/36) of the shares subject to the option shall vest each month thereafter. Read SEC document
March 02, 2020 Filed Mar 3, 2020 18:51 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	4,543	$9.68	$43,976.24	Disclosure SEC source: 0001209191-20-015647 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,229 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F2 · balance_after: Includes 1,239 shares acquired under the Issuer's employee stock purchase plan on February 28, 2020. Read SEC document
February 24, 2020 Filed Feb 26, 2020 20:10 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantPerformance Stock Unit · Derivative	73,125	$0.00	$0.00	Disclosure SEC source: 0001209191-20-013253 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,125 Underlying: Common Stock · 73,125 shares Expires 2023-02-24 F1 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one (1) share of the Issuer's common stock. F2 · derivative.exercise_price: One-third of the PSUs will be earned one or after the one (1) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 50% per share from the grant date closing price of Issuer's Common Stock on the Nasdaq Global Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F3 · derivative.exercise_price: One-third of the PSUs will be earned on or after the two (2) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 100% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F4 · derivative.exercise_price: One-third of the PSUs will be earned on the three (3) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 150% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (2) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F2 · derivative.exercise_date: One-third of the PSUs will be earned one or after the one (1) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 50% per share from the grant date closing price of Issuer's Common Stock on the Nasdaq Global Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F3 · derivative.exercise_date: One-third of the PSUs will be earned on or after the two (2) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 100% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F4 · derivative.exercise_date: One-third of the PSUs will be earned on the three (3) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 150% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (2) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. Read SEC document
February 03, 2020 Filed Feb 4, 2020 18:51 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	3,435	$12.89	$44,277.15	Disclosure SEC source: 0001209191-20-006640 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,533 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
January 31, 2020 Filed Feb 4, 2020 18:51 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	65,000	$0.00 Strike: $12.79	$0.00	Disclosure SEC source: 0001209191-20-006640 · doc4.xml · derivative · entry 3 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-01-30 F3 · derivative.exercise_date: The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2020, subject to the Reporting Person's Continuous Service as of each such date. Read SEC document
January 31, 2020 Filed Feb 4, 2020 18:51 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	16,250	$0.00	$0.00	Disclosure SEC source: 0001209191-20-006640 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,968 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs vest in three equal annual installments subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each vest date. Read SEC document
January 14, 2020 Filed Jan 14, 2020 19:45 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	1,277	$13.80	$17,622.60	Disclosure SEC source: 0001209191-20-003374 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,718 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
January 12, 2020 Filed Jan 14, 2020 19:45 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	2,125	$0.00	$0.00	Disclosure SEC source: 0001209191-20-003374 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,995 F1 · shares: Each Performance Stock Unit ("PSU") granted March 29, 2018 represented a contingent right to receive one share of Issuer's Common Stock. 2,125 PSUs time-vested on January 12, 2020 on the one year anniversary of the certification by the Issuer's Compensation Committee of the FDA's December 31, 2018 approval of Andexxa Gen 2 in the United States. F2 · balance_after: Includes 425 shares of common stock acquired under the PTLA stock purchase plan on August 30, 2019 in an exempt transaction. Read SEC document
June 05, 2019 Filed Jun 6, 2019 16:15 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $4.80	$0.00	Disclosure SEC source: 0001209191-19-035054 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-04 F1 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 5, 2019, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document
May 20, 2019 Filed May 21, 2019 20:28 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	3,022	$28.69	$86,701.18	Disclosure SEC source: 0001209191-19-031877 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,570 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
May 19, 2019 Filed May 21, 2019 20:28 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Exercise / conversionPerformance Stock Unit · Derivative	5,859	$0.00	$0.00	Disclosure SEC source: 0001209191-19-031877 · doc4.xml · derivative · entry 3 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,859 shares Expires 2027-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") granted January 30, 2017 represented a contingent right to receive one (1) share of the Issuer's Common Stock. 5,859 became vested on the upon the first anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018. F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") granted January 30, 2017 represented a contingent right to receive one (1) share of the Issuer's Common Stock. 5,859 became vested on the upon the first anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018. Read SEC document
May 19, 2019 Filed May 21, 2019 20:28 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	5,859	$0.00	$0.00	Disclosure SEC source: 0001209191-19-031877 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,592 F1 · shares: Each Performance Stock Unit ("PSU") granted January 30, 2017 represented a contingent right to receive one (1) share of the Issuer's Common Stock. 5,859 became vested on the upon the first anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018. Read SEC document
April 04, 2019 Filed Apr 8, 2019 19:03 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	SaleCommon Stock	40,486	$37.39	$1,513,824.17	Disclosure SEC source: 0001209191-19-024043 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,733 F1 · shares: The sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.1000 to $37.7400, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) to this Form 4. Read SEC document
March 04, 2019 Filed Mar 5, 2019 18:26 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	9,667	$33.41	$322,974.47	Disclosure SEC source: 0001209191-19-016965 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,219 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
January 31, 2019 Filed Feb 4, 2019 17:47 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $27.10	$0.00	Disclosure SEC source: 0001209191-19-006896 · doc4.xml · derivative · entry 2 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-30 F2 · derivative.exercise_date: The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2019, subject to the Reporting Person's Continuous Service as of each such date. Read SEC document
January 31, 2019 Filed Feb 4, 2019 17:47 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	18,750	$0.00	$0.00	Disclosure SEC source: 0001209191-19-006896 · doc4.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,682 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs vest in three equal annual installments on January 31, 2020, January 31, 2021 and January 31, 2022, subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.